Sanford Dialysis Red Lake is a medicare approved dialysis facility center in Red Lake, Minnesota and it has 5 dialysis stations. It is located in Beltrami county at Red Lake Hospital, Red Lake, MN, 56671. You can reach out to the office of Sanford Dialysis Red Lake at (218) 679-3117. This dialysis clinic is managed and/or owned by Sanford Health. Sanford Dialysis Red Lake has the following ownership type - Non-Profit. It was first certified by medicare in March, 2005. The medicare id for this facility is 243534 and it accepts patients under medicare ESRD program.
| Name | Sanford Dialysis Red Lake |
|---|---|
| Location | Red Lake Hospital, Red Lake, Minnesota |
| No. of Dialysis Stations | 5 |
| Medicare ID | 243534 |
| Managed By | Sanford Health |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| Red Lake Hospital, Red Lake, Minnesota, 56671 | |
| (218) 679-3117 | |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.
A team of scientists at the Helmholtz Zentrum München together with colleagues of the Ludwig Maximilians University Munich recently developed a new strategy to determine monocyte subsets involved in diseases. The results published in the journal 'Blood' could help facilitating the diagnosis of sarcoidosis and may improve the respective patient management.
Today's headlines include the latest on the budget negotiations as well as examinations of what's happening with the health law's online insurance marketplaces.
Cancer researchers at Queen's University Belfast have made a breakthrough which could signal new treatments for women at high risk of breast and ovarian cancer.
› Verified 4 days ago
| NPI Number | 1124189741 |
| Organization Name | Sanford Dialysis Red Lake |
| Doing Business As | Sanford Medical Center Fargo |
| Address | Highway 1 Red Lake, Minnesota, 56671 |
| Phone Number | (218) 679-3117 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.
A team of scientists at the Helmholtz Zentrum München together with colleagues of the Ludwig Maximilians University Munich recently developed a new strategy to determine monocyte subsets involved in diseases. The results published in the journal 'Blood' could help facilitating the diagnosis of sarcoidosis and may improve the respective patient management.
Today's headlines include the latest on the budget negotiations as well as examinations of what's happening with the health law's online insurance marketplaces.
Cancer researchers at Queen's University Belfast have made a breakthrough which could signal new treatments for women at high risk of breast and ovarian cancer.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 21 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 48 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.
A team of scientists at the Helmholtz Zentrum München together with colleagues of the Ludwig Maximilians University Munich recently developed a new strategy to determine monocyte subsets involved in diseases. The results published in the journal 'Blood' could help facilitating the diagnosis of sarcoidosis and may improve the respective patient management.
Today's headlines include the latest on the budget negotiations as well as examinations of what's happening with the health law's online insurance marketplaces.
Cancer researchers at Queen's University Belfast have made a breakthrough which could signal new treatments for women at high risk of breast and ovarian cancer.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 30 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 233 |
| Percentage of adult patients getting regular hemodialysis at the center | 85 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.
A team of scientists at the Helmholtz Zentrum München together with colleagues of the Ludwig Maximilians University Munich recently developed a new strategy to determine monocyte subsets involved in diseases. The results published in the journal 'Blood' could help facilitating the diagnosis of sarcoidosis and may improve the respective patient management.
Today's headlines include the latest on the budget negotiations as well as examinations of what's happening with the health law's online insurance marketplaces.
Cancer researchers at Queen's University Belfast have made a breakthrough which could signal new treatments for women at high risk of breast and ovarian cancer.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Sanford Dialysis Red Lake with elevated calcium levels.
| Patients with hypercalcemia | 32 |
| Hypercalcemia patient months | 269 |
| Patients with Serumphosphor | 33 |
| Patients with Serumphosphor less than 3.5 mg/dL | 4 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 17 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 26 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 30 |
| Patients with Serumphosphor greater than 7 mg/dL | 23 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.
A team of scientists at the Helmholtz Zentrum München together with colleagues of the Ludwig Maximilians University Munich recently developed a new strategy to determine monocyte subsets involved in diseases. The results published in the journal 'Blood' could help facilitating the diagnosis of sarcoidosis and may improve the respective patient management.
Today's headlines include the latest on the budget negotiations as well as examinations of what's happening with the health law's online insurance marketplaces.
Cancer researchers at Queen's University Belfast have made a breakthrough which could signal new treatments for women at high risk of breast and ovarian cancer.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 29 |
| Patient months included in arterial venous fistula and catheter summaries | 246 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 88 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 10 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.
A team of scientists at the Helmholtz Zentrum München together with colleagues of the Ludwig Maximilians University Munich recently developed a new strategy to determine monocyte subsets involved in diseases. The results published in the journal 'Blood' could help facilitating the diagnosis of sarcoidosis and may improve the respective patient management.
Today's headlines include the latest on the budget negotiations as well as examinations of what's happening with the health law's online insurance marketplaces.
Cancer researchers at Queen's University Belfast have made a breakthrough which could signal new treatments for women at high risk of breast and ovarian cancer.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 24 |
| Hospitalization Rate in facility | 216.2 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 414.1 |
| Hospitalization Rate: Lower Confidence Limit | 118.8 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.
A team of scientists at the Helmholtz Zentrum München together with colleagues of the Ludwig Maximilians University Munich recently developed a new strategy to determine monocyte subsets involved in diseases. The results published in the journal 'Blood' could help facilitating the diagnosis of sarcoidosis and may improve the respective patient management.
Today's headlines include the latest on the budget negotiations as well as examinations of what's happening with the health law's online insurance marketplaces.
Cancer researchers at Queen's University Belfast have made a breakthrough which could signal new treatments for women at high risk of breast and ovarian cancer.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at Sanford Dialysis Red Lake were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 33.6 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 43.6 |
| Readmission Rate: Lower Confidence Limit | 24 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.
A team of scientists at the Helmholtz Zentrum München together with colleagues of the Ludwig Maximilians University Munich recently developed a new strategy to determine monocyte subsets involved in diseases. The results published in the journal 'Blood' could help facilitating the diagnosis of sarcoidosis and may improve the respective patient management.
Today's headlines include the latest on the budget negotiations as well as examinations of what's happening with the health law's online insurance marketplaces.
Cancer researchers at Queen's University Belfast have made a breakthrough which could signal new treatments for women at high risk of breast and ovarian cancer.
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Sanford Dialysis Red Lake get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .5 (As Expected) |
| SIR: Upper Confidence Limit | 2.46 |
| SIR: Lower Confidence Limit | .03 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.
A team of scientists at the Helmholtz Zentrum München together with colleagues of the Ludwig Maximilians University Munich recently developed a new strategy to determine monocyte subsets involved in diseases. The results published in the journal 'Blood' could help facilitating the diagnosis of sarcoidosis and may improve the respective patient management.
Today's headlines include the latest on the budget negotiations as well as examinations of what's happening with the health law's online insurance marketplaces.
Cancer researchers at Queen's University Belfast have made a breakthrough which could signal new treatments for women at high risk of breast and ovarian cancer.
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Sanford Dialysis Red Lake's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 21 |
| Transfusion Rate in facility | 47 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 178.6 |
| Transfusion Rate: Lower Confidence Limit | 14.6 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.
A team of scientists at the Helmholtz Zentrum München together with colleagues of the Ludwig Maximilians University Munich recently developed a new strategy to determine monocyte subsets involved in diseases. The results published in the journal 'Blood' could help facilitating the diagnosis of sarcoidosis and may improve the respective patient management.
Today's headlines include the latest on the budget negotiations as well as examinations of what's happening with the health law's online insurance marketplaces.
Cancer researchers at Queen's University Belfast have made a breakthrough which could signal new treatments for women at high risk of breast and ovarian cancer.
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at Sanford Dialysis Red Lake lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 116 |
| Mortality Rate in facility | 20.1 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 30.7 |
| Mortality Rate: Lower Confidence Limit | 12.4 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.
A team of scientists at the Helmholtz Zentrum München together with colleagues of the Ludwig Maximilians University Munich recently developed a new strategy to determine monocyte subsets involved in diseases. The results published in the journal 'Blood' could help facilitating the diagnosis of sarcoidosis and may improve the respective patient management.
Today's headlines include the latest on the budget negotiations as well as examinations of what's happening with the health law's online insurance marketplaces.
Cancer researchers at Queen's University Belfast have made a breakthrough which could signal new treatments for women at high risk of breast and ovarian cancer.
› Verified 4 days ago
Sanford Dialysis Red Lake Location: Red Lake Hospital, Red Lake, Minnesota, 56671 Phone: (218) 679-3117 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.
A team of scientists at the Helmholtz Zentrum München together with colleagues of the Ludwig Maximilians University Munich recently developed a new strategy to determine monocyte subsets involved in diseases. The results published in the journal 'Blood' could help facilitating the diagnosis of sarcoidosis and may improve the respective patient management.
Today's headlines include the latest on the budget negotiations as well as examinations of what's happening with the health law's online insurance marketplaces.
Cancer researchers at Queen's University Belfast have made a breakthrough which could signal new treatments for women at high risk of breast and ovarian cancer.
› Verified 4 days ago